ANI Pharmaceuticals

Market position

ANI competes in the specialty and generic drug manufacturing industry alongside companies such as Amneal, Perrigo, Collegium and Pacira, with a market capitalization of roughly $1.73 billion as of August 2026 and trailing twelve-month revenue of about $978 million.

The company combines a growing rare disease franchise led by Purified Cortrophin Gel and ophthalmic implants with a generics R&D engine noted for a large number of Competitive Generic Therapy approvals and 505(b)(2) development, supported by U.S.-based manufacturing that also serves CDMO customers.

Technology

ANI operates U.S.-based manufacturing sites capable of producing oral solid dose, semi-solid, liquid, topical, injectable, controlled-substance and potent products. Its R&D capabilities, expanded through the Novitium Pharma acquisition, target complex generics and 505(b)(2) candidates, including products with FDA Competitive Generic Therapy designation. Rare disease assets include fluocinolone acetonide intravitreal implants (ILUVIEN, YUTIQ) studied in non-infectious posterior segment uveitis.

Go-to-market

Products are distributed in the U.S. through wholesalers, specialty pharmacies, chain and mail-order pharmacies, GPOs and hospital/provider channels. The company supports its rare disease brands with dedicated commercial teams and participates in investor and industry conferences such as the Jefferies Global Healthcare Conference.

National wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers; end patients include adults and children with rare, ophthalmic, neurologic and other chronic conditions.

Geography

Headquartered in Baudette, Minnesota, with press releases issued from Princeton, New Jersey, and New Jersey-based manufacturing and development operations added through the Novitium acquisition. Products are marketed in the United States and internationally.

History

The company was incorporated in 2001 (a third-party database lists a 1996 founding year) and is headquartered in Baudette, Minnesota. Nikhil Lalwani joined as President and CEO in September 2020, following roles at Cipla and McKinsey & Company. In November 2021 ANI completed the acquisition of New Jersey-based Novitium Pharma, adding R&D, manufacturing and commercialization capabilities and bringing Novitium founders Samy Shanmugam, Chad Gassert and Vijay Thorappadi plus more than 100 employees into the company. In 2024 ANI pursued and worked toward closing the acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM), which brought ophthalmic assets including ILUVIEN and YUTIQ into the portfolio.

Risks & controversies

ANI is engaged in litigation concerning assets it sold to CG Oncology in 2010, with an intent to appeal rulings to the Delaware Supreme Court. Analyst commentary in 2026 highlighted a cut to Cortrophin sales guidance and associated execution risk, and the shares carry a Hold investment rating from at least one research provider with a Low financial strength subrating. The company's capital structure includes substantial debt, with total debt to equity of about 105%.